Compare FLYX & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FLYX | COCH |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Blank Checks |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.1M | 51.0M |
| IPO Year | 2021 | 2021 |
| Metric | FLYX | COCH |
|---|---|---|
| Price | $1.14 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 287.0K | 75.0K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.61 | ★ 17.45 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $375,877,000.00 | $241,000.00 |
| Revenue This Year | $10.47 | $1.58 |
| Revenue Next Year | $15.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 14.85 | 7.11 |
| 52 Week Low | $1.05 | $0.36 |
| 52 Week High | $8.88 | $1.89 |
| Indicator | FLYX | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 41.42 | 45.31 |
| Support Level | $1.13 | $0.63 |
| Resistance Level | $1.36 | $0.73 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 18.52 | 14.29 |
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet, which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.